<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
h1
	{mso-style-link:"Heading 1 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	line-height:107%;
	page-break-after:avoid;
	font-size:16.0pt;
	font-family:"Calibri Light",sans-serif;
	color:#2F5496;
	font-weight:normal;}
h3
	{mso-style-link:"Heading 3 Char";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	line-height:107%;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Calibri Light",sans-serif;
	color:#1F3763;
	font-weight:normal;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.5in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.5in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-link:"Heading 1";
	font-family:"Calibri Light",sans-serif;
	color:#2F5496;}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	mso-style-link:"Heading 3";
	font-family:"Calibri Light",sans-serif;
	color:#1F3763;}
.MsoChpDefault
	{font-family:"Calibri",sans-serif;}
.MsoPapDefault
	{margin-bottom:8.0pt;
	line-height:107%;}
@page WordSection1
	{size:595.3pt 841.9pt;
	margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-GB>

<div class=WordSection1>

<h1><span style='font-size:15.0pt;line-height:107%'>2004B02 Write a brief
description of the pharmacology of ropivacaine.</span></h1>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt'>&nbsp;</p>

<h3><span style='font-size:13.0pt;line-height:107%'>List:</span></h3>

<p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:22.5pt;margin-bottom:.0001pt;text-indent:-13.5pt'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>PC</p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:22.5pt;margin-bottom:.0001pt;text-indent:-13.5pt'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>PK</p>

<p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:22.5pt;margin-bottom:.0001pt;text-indent:-13.5pt'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>PD</p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt'>&nbsp;</p>

<h3><span style='font-size:13.0pt;line-height:107%'>Physicochemical:</span></h3>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=108 valign=top style='width:80.75pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'>Class</p>
  </td>
  <td width=493 valign=top style='width:370.05pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraph style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:15.75pt;margin-bottom:.0001pt;text-indent:-9.0pt;line-height:
  normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span>Mepivacaine series</p>
  </td>
 </tr>
 <tr>
  <td width=108 valign=top style='width:80.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'>Structure</p>
  </td>
  <td width=493 valign=top style='width:370.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:15.75pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span>Lipid soluble modified benzene ring</p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:15.75pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span>Intermediate chain with amide bond</p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:15.75pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span>Terminal amine: piperidine ring with propyl (C<sub>3</sub>H<sub>7</sub>)
  addition</p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:15.75pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span>Exhibits optical stereoisomerism:</p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:.55in;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span style='font-family:"Courier New"'>o<span
  style='font:7.0pt "Times New Roman"'> </span></span>S enantiomer more potent
  and less toxic</p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:.55in;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span style='font-family:"Courier New"'>o<span
  style='font:7.0pt "Times New Roman"'> </span></span>Hence produced as an
  enantiopure preparation</p>
  </td>
 </tr>
 <tr>
  <td width=108 valign=top style='width:80.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'>Behaviour</p>
  </td>
  <td width=493 valign=top style='width:370.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:15.75pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span>Lipid solubility very high 300x procaine -&gt; &#8593;potency,
  &#8593;toxicity</p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:15.75pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span>Weak base. pKa 8.1</p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:15.75pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span>15% unionized at ECF pH (7.4) (cf. 25% lignocaine) -&gt; slower
  onset</p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:15.75pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span>90% ionized at ICF pH (6.8)</p>
  </td>
 </tr>
 <tr>
  <td width=108 valign=top style='width:80.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'>Formulation</p>
  </td>
  <td width=493 valign=top style='width:370.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:15.75pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span>Aqueous solution</p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:15.75pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span>0.2%, 0.75%, 1%</p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:15.75pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span>No added adrenaline due to intrinsic vasoconstrictor property</p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt'>&nbsp;</p>

<h3><span style='font-size:13.0pt;line-height:107%'>Pharmacokinetics:</span></h3>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=108 valign=top style='width:80.75pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'>Administration</p>
  </td>
  <td width=493 valign=top style='width:370.05pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraph style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:15.75pt;margin-bottom:.0001pt;text-indent:-9.0pt;line-height:
  normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span>Routes: subcut, around peripheral nerve or plexus, epidural,
  subarachnoid</p>
  </td>
 </tr>
 <tr>
  <td width=108 valign=top style='width:80.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'>Time course</p>
  </td>
  <td width=493 valign=top style='width:370.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:15.75pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span>Dependent upon location</p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:15.75pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span>Medium onset ~30 mins for large peripheral nerve block</p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:15.75pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span>Duration long ~12-24 hours for large peripheral nerve block</p>
  </td>
 </tr>
 <tr>
  <td width=108 valign=top style='width:80.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'>Absorption</p>
  </td>
  <td width=493 valign=top style='width:370.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraph style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:15.75pt;margin-bottom:.0001pt;text-indent:-9.0pt;line-height:
  normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span>Rate: tracheal &gt; intercostal &gt; caudal &gt; paracervical
  &gt; epidural &gt; plexus &gt; peripheral nerve</p>
  </td>
 </tr>
 <tr>
  <td width=108 valign=top style='width:80.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'>Distribution</p>
  </td>
  <td width=493 valign=top style='width:370.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:15.75pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span>94% plasma protein bound</p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:15.75pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span>Highly tissue protein bound -&gt; &#8593;duration of action</p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:15.75pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span>V<sub>D</sub> 0.5L/kg</p>
  </td>
 </tr>
 <tr>
  <td width=108 valign=top style='width:80.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'>Metabolism</p>
  </td>
  <td width=493 valign=top style='width:370.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:15.75pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span>Hepatic CYP450</p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:15.75pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span>Metabolites: 3-OH and 3-OH-ropivacaine; both have some LA activity</p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:15.75pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span>t<sub>1/2</sub><sub>&#946;</sub> 120mins</p>
  </td>
 </tr>
 <tr>
  <td width=108 valign=top style='width:80.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'>Excretion</p>
  </td>
  <td width=493 valign=top style='width:370.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraph style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:15.75pt;margin-bottom:.0001pt;text-indent:-9.0pt;line-height:
  normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span>Metabolites -&gt; urine</p>
  </td>
 </tr>
 <tr>
  <td width=108 valign=top style='width:80.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'>Comparison with bupivacaine</p>
  </td>
  <td width=493 valign=top style='width:370.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:15.75pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span>&#8595;t<sub>1/2</sub><sub>&#946;</sub> -&gt; &#8595;duration
  toxicity</p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:15.75pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span>Vasoconstriction -&gt; &#8595;rate of systemic absorption -&gt;
  &#8595;peak plasma concentration</p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt'>&nbsp;</p>

<h3><span style='font-size:13.0pt;line-height:107%'>Pharmacodynamics:</span></h3>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=108 valign=top style='width:80.75pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'>Target</p>
  </td>
  <td width=493 valign=top style='width:370.05pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:7.95pt;margin-bottom:.0001pt;text-indent:-7.95pt;
  line-height:normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;
  </span></span>Voltage-dependent Na<sup>+</sup> channel (VDNaC)</p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:7.95pt;margin-bottom:.0001pt;text-indent:-7.95pt;
  line-height:normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;
  </span></span>(less active at VDKC, VDCaC)</p>
  </td>
 </tr>
 <tr>
  <td width=108 valign=top style='width:80.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'>Entry</p>
  </td>
  <td width=493 valign=top style='width:370.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:7.95pt;margin-bottom:.0001pt;text-indent:-7.95pt;
  line-height:normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;
  </span></span>From ICF: unionised form diffuses into axoplasm, ionised form
  enters active receptor</p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:7.95pt;margin-bottom:.0001pt;text-indent:-7.95pt;
  line-height:normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;
  </span></span>From ECF: ionised form enters active receptor (less common)</p>
  </td>
 </tr>
 <tr>
  <td width=108 valign=top style='width:80.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'>Binding</p>
  </td>
  <td width=493 valign=top style='width:370.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:7.95pt;margin-bottom:.0001pt;text-indent:-7.95pt;
  line-height:normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;
  </span></span>Rate <span style='font-family:"Cambria Math",serif'>&#8733;</span>
  time spent in active state <span style='font-family:"Cambria Math",serif'>&#8733;</span>
  rate of cycling <span style='font-family:"Cambria Math",serif'>&#8733;</span>
  nerve activity</p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:7.95pt;margin-bottom:.0001pt;text-indent:-7.95pt;
  line-height:normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;
  </span></span>Affinity <span style='font-family:"Cambria Math",serif'>&#8733;</span>
  Inactive &gt; resting &gt; activated</p>
  </td>
 </tr>
 <tr>
  <td width=108 valign=top style='width:80.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'>Effect</p>
  </td>
  <td width=493 valign=top style='width:370.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:7.95pt;margin-bottom:.0001pt;text-indent:-7.95pt;
  line-height:normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;
  </span></span>&#8595;Rate of cycling -&gt; no action potential propagation</p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:7.95pt;margin-bottom:.0001pt;text-indent:-7.95pt;
  line-height:normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;
  </span></span>Initial: incomplete blockade, tonic</p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:7.95pt;margin-bottom:.0001pt;text-indent:-7.95pt;
  line-height:normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;
  </span></span>Repeated stimulation: complete blockade, phasic</p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:7.95pt;margin-bottom:.0001pt;text-indent:-7.95pt;
  line-height:normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;
  </span></span>No change to resting potential</p>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><span style='font-size:12.0pt'><img width=318 height=220
  id="Picture 1" src="2004B02_ropivacaine_files/image001.jpg"></span></p>
  </td>
 </tr>
 <tr>
  <td width=108 valign=top style='width:80.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'>Comparison with bupivacaine</p>
  </td>
  <td width=493 valign=top style='width:370.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:15.75pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span>Motor block slower onset, &#8595; density, faster offset than
  bupivacaine</p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:.55in;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span style='font-family:"Courier New"'>o<span
  style='font:7.0pt "Times New Roman"'> </span></span>Allows differential
  blockade (i.e. sensory but not motor)</p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:15.75pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span>&#8595; affinity for cardiac VDNaC -&gt; &#8595;CC:CNS</p>
  </td>
 </tr>
 <tr>
  <td width=108 valign=top style='width:80.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'>LAST</p>
  </td>
  <td width=493 valign=top style='width:370.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'>Numbers:</p>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:15.75pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span>Toxic concentration: 4mcg/mL (CVS collapse)</p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:15.75pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span>Max safe subcut dose 3mg/kg</p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:15.75pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span>CC:CNS ratio 5:1 (cf. 3:1 bupiv, 7:1 ligno)</p>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'>CNS effects:</p>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:15.75pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span>Initial excitatory (block inhibitory interneurons): peri-oral
  tingling, vertigo, tinnitus, inattention, slurred speech, twitching, seizure</p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:15.75pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span>Then inhibitory (block excitatory interneuron): coma, apneoa</p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:15.75pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span>Hyperventilation -&gt; &#8595;PaCO<sub>2</sub> -&gt; cerebral
  vasoconstriction -&gt; &#8595;toxicity</p>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'>CVS effects:</p>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:15.75pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span>First phase: &#8593;HR, &#8593;mAP</p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:15.75pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span>Second phase: myocardial depression, &#8595;mAP</p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:15.75pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span>Terminal phase: peripheral vasodilatation, severe &#8595;mAP,
  arrythmia, arrest</p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:15.75pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span>Arrhythmias: sinus bradycardia, AV block, ventricular
  tachyarrhythmia, asystole</p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt'>&nbsp;</p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt'>&nbsp;</p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt'>&nbsp;</p>

</div>

</body>

</html>
